Smith & Nephew SNATS Inc (SNN) stock: key figures, P/E, revenue and dividend
Health Care · Health Care Equipment · United States · ISIN US83175M2052
Smith & Nephew SNATS Inc financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 5.81 bn USD | 6.16 bn USD |
| Gross profit | 4.08 bn USD | 4.21 bn USD |
| Operating income | 657.00 m USD | 794.00 m USD |
| EBIT | 886.00 m USD | 877.00 m USD |
| Net income | 412.00 m USD | 625.00 m USD |
| Diluted EPS – continuing operations | 0.94 USD | 1.43 USD |
Full history since 1985, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Smith & Nephew SNATS Inc
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
More stocks
- Chongqing Sokon Ind Grp Co (601127.SS)
- Taiwan Mobile Co Ltd (3045.TW)
- CoStar Group (CSGP)
- Tokyo Gas Co Ltd (TKGSY)
- Puig Brands SA (PUIG.MC)
- Toromont Industries Ltd (TIH.TO)
- AMERICAN FINANCIAL GROUP INC (AFG)
- MMG Ltd (1208.HK)
- Obayashi Corp (1802.T)
- FIVE BELOW, INC (FIVE)
- Realtek Semiconductor Corp (2379.TW)
- Zhejiang Nhu Co Ltd (002001.SZ)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.